Comparative Pharmacology
Head-to-head clinical analysis: ADIPEX P versus MELFIAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADIPEX P versus MELFIAT.
ADIPEX-P vs MELFIAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phentermine is a sympathomimetic amine that stimulates release of norepinephrine and to a lesser extent dopamine and serotonin from presynaptic nerve terminals in the hypothalamic feeding center, resulting in appetite suppression.
Melfiat is a sympathomimetic amine that acts as an anorectic agent. Its mechanism of action involves stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to suppression of appetite.
Phentermine (ADIPEX-P) is typically dosed as 15–37.5 mg orally once daily, administered 2 hours after breakfast or before breakfast. The 37.5 mg tablet is taken once daily before breakfast or 1–2 hours after breakfast; some patients may require 15 mg or 30 mg (half of a 37.5 mg tablet) once daily. The extended-release formulation (ADIPEX-P) is not available; only immediate-release tablets are marketed. Duration of therapy should be limited to a few weeks (e.g., 4–12 weeks) due to potential for tolerance and abuse.
1 to 2 tablets (75 to 150 mg mazindol) orally once daily with breakfast.
None Documented
None Documented
Terminal half-life approximately 20-25 hours. Clinical context: Steady-state reached within 4-5 days; dosing adjustments may be needed in renal impairment.
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in renal impairment.
Primarily renal (70-90% unchanged); minor biliary/fecal (10-30% as metabolites). Urinary pH-dependent; acidic urine increases excretion.
Primarily renal (70-80% as unchanged drug and metabolites), with ~20% eliminated via bile into feces.
Category C
Category C
Anorexiant
Anorexiant